Neurofibromatosis Type 2 (NF2)

  • D. Gareth R. Evans


Neurofibromatosis type 2 (NF2), Bilateral acoustic neurofibromatosis, Central neurofibromatosis. OMIM #101000. The correct name for the condition is Neurofibromatosis type 2 (NF2). The remaining names are historically due to the overlap with NF1 and previous confusion over the two conditions. The first clear description of NF2 was in 1822 by Wishart.


Vestibular Schwannoma Choroid Plexus Carcinoma Magnetic Resonance Imaging Screening Auditory Brainstem Implant Intermedius Nerve 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wishart JH. Case of tumours in the skull, dura mater, and brain. Edinburgh Med Surg J. 1822;18:393-397.Google Scholar
  2. 2.
    Cushing H. Tumours of the Nervus Acusticus and the Syndrome of the Cerebello-pontine Angle. Philadelphia: WB Saunders; 1917.Google Scholar
  3. 3.
    Crowe FW, Schull WJ, Neal JV, eds. A Clinical Pathological and Genetic Study of Multiple Neurofibromatosis. Springfield, IL: Charles C. Thomas; 1956.Google Scholar
  4. 4.
    Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature. 1993;363:515-521.PubMedCrossRefGoogle Scholar
  5. 5.
    Troffater JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumour suppressor. Cell. 1993;72:791-800.CrossRefGoogle Scholar
  6. 6.
    National Institutes of Health Consensus Development Conference. Statement on neurofibromatosis. Arch Neurol. 1987;45:575-579.CrossRefGoogle Scholar
  7. 7.
    Evans DGR, Huson S, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84:603-618.PubMedGoogle Scholar
  8. 8.
    Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the north west of England and the UK: I. Prevalence, mutation rate, fitness and confirmation of maternal transmission effect on severity. J Med Genet. 1992;29:841-846.PubMedCrossRefGoogle Scholar
  9. 9.
    Evans DGR, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10 year period: higher incidence than previously thought. Otol Neurotol. 2005;26(1):93-97.PubMedCrossRefGoogle Scholar
  10. 10.
    Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service. Am J Med Genet. 2010;152A(2):327-332.PubMedCrossRefGoogle Scholar
  11. 11.
    Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jääskeläinen J. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology. 2000;54(1):71-76.PubMedCrossRefGoogle Scholar
  12. 12.
    Evans DGR, Wallace A, Trueman L, Strachan T. Mosaicism in classical neurofibromatosis type 2: a common mechanism for ­sporadic disease in tumour prone syndromes? Am J Hum Genet. 1998;63:727-736.PubMedGoogle Scholar
  13. 13.
    Evans DGR, Ramsden RT, Shenton A, et al. Mosaicism in NF2 an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including MLPA. J Med Genet. 2007;44(7):424-428.PubMedCrossRefGoogle Scholar
  14. 14.
    Kluwe L, Mautner VF, Heinrich B, et al. Molecular study of ­frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet. 2003;40:109-114.PubMedCrossRefGoogle Scholar
  15. 15.
    Moyhuddin A, Baser ME, Watson C, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet. 2003;40:459-463.PubMedCrossRefGoogle Scholar
  16. 16.
    Kanter WR, Eldridge R, Fabricant R, Allen JC, Koerber T. Central neurofibromatosis with bilateral acoustic neuroma. Genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology. 1980;30:851-859.PubMedCrossRefGoogle Scholar
  17. 17.
    Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52:450-451.PubMedCrossRefGoogle Scholar
  18. 18.
    Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery. 1996;38:880-885.PubMedCrossRefGoogle Scholar
  19. 19.
    Evans DGR, Ramsden R, Birch J. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child. 1999;81:496-499.PubMedCrossRefGoogle Scholar
  20. 20.
    Trivedi R, Byrne J, Huson SM, Donaghy M. Focal amyotrophy in neurofibromatosis 2. J Neurol Neurosurg Psychiatry. 2000;69(2):257-261.PubMedCrossRefGoogle Scholar
  21. 21.
    Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain. 2002;125:996-1004.PubMedCrossRefGoogle Scholar
  22. 22.
    Evans DGR, Newton V, Neary W, et al. Use of MRI and audiological tests in pre-symptomatic diagnosis of type 2 neurofibromatosis (NF2). J Med Genet. 2000;37:944-947.PubMedCrossRefGoogle Scholar
  23. 23.
    King A, Biggs N, Ramsden RT, Wallace A, Gillespie J, Evans DGR. Spinal tumours in neurofibromatosis type 2: Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine. 2005;2(5):574-579.PubMedCrossRefGoogle Scholar
  24. 24.
    Evans DGR, Baser ME, O’Reilly B, et al. Management of the patient and family with Neurofibromatosis 2: a consensus conference statement. Brit J Neurosurg. 2005;19:5-12.CrossRefGoogle Scholar
  25. 25.
    Evans DGR, Ramsden RT, Shenton A, et al. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet. 2007;71(4):354-358.PubMedCrossRefGoogle Scholar
  26. 26.
    Evans DGR, Ramsden RT, Shenton A, et al. What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumours? J Neurosurg. 2008;108(1):92-96.PubMedCrossRefGoogle Scholar
  27. 27.
    Seizinger BR, Rouleau GA, Ozelius LG, et al. Genetic linkage of von Recklinghausen neurofibromatosis to the nerve growth factor receptor gene. Cell. 1987;49:589-594.PubMedCrossRefGoogle Scholar
  28. 28.
    Rouleau G, Seizinger BR, Ozelius LG, et al. Genetic linkage analysis of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature. 1987;329:246-248.PubMedCrossRefGoogle Scholar
  29. 29.
    Parry DM, MacCollin M, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet. 1996;59:529-539.PubMedGoogle Scholar
  30. 30.
    Ruttledge MH, Andermann AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet. 1996;59:331-342.PubMedGoogle Scholar
  31. 31.
    Kluwe L, Bayer S, Baser ME, Hazim W, Haase W, Funsterer C. Mautner VF Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes [published erratum in Hum Genet 1997;99(2):292]. Hum Genet. 1996;98:534-538.PubMedCrossRefGoogle Scholar
  32. 32.
    Kluwe L, MacCollin M, Tatagiba M, et al. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. Am J Med Genet. 1998;77:228-233.PubMedCrossRefGoogle Scholar
  33. 33.
    Evans DGR, Trueman L, Wallace A, Mason S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis: evidence for more severe disease with truncating mutations. J Med Genet. 1998;35:450-455.PubMedCrossRefGoogle Scholar
  34. 34.
    Baser ME, Kuramoto L, Joe H, et al. Genotype-phenotype correlations for nervous system tumours in neurofibromatosis 2: a population-based study. Am J Hum Genet. 2004;75:231-239.PubMedCrossRefGoogle Scholar
  35. 35.
    Baser ME, Kuramoto L, Woods RH, et al. The location of constitutional neurofibromatosis 2 (NF2) splice-site mutations is associated with the severity of NF2. J Med Genet. 2005;42(7):540-546.PubMedCrossRefGoogle Scholar
  36. 36.
    Selvanathan SK, Shenton A, Ferner R, et al. Further genotype-phenotype correlations in neurofibromatosis type 2. Clin Genet. 2010;77(2):163-170.PubMedCrossRefGoogle Scholar
  37. 37.
    Tsilchorozidou T, Menko F, Lalloo F, et al. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis type 2. J Med Genet. 2004;41(7):529-534.PubMedCrossRefGoogle Scholar
  38. 38.
    Kluwe L, Nygren AO, Errami A, et al. Screening for large mutations of the NF2 gene. Genes Chromosomes Cancer. 2005;42(4):384-391.PubMedCrossRefGoogle Scholar
  39. 39.
    MacCollin M, Chiocca EA, Evans DG, et al. Diagnostic criteria for schwannomatosis. Neurology. 2005;64(11):1838-1845.PubMedCrossRefGoogle Scholar
  40. 40.
    Murray A, Hughes TAT, Neal JW, Howard E, Evans DGR, Harper PS. A case of multiple cutaneous schwannomas; schwannomatosis or neurofibromatosis type 2? J Neurol Neurosurg Psychiatry. 2006;77(2):269-271.PubMedCrossRefGoogle Scholar
  41. 41.
    Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology. 2006;66(5):730-732.PubMedCrossRefGoogle Scholar
  42. 42.
    Hadfield KD, Newman WG, Bowers NL, et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet. 2008;45(6):332-339.PubMedCrossRefGoogle Scholar
  43. 43.
    Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DGR. Evaluation of diagnostic criteria for neurofibromatosis 2. Neurology. 2002;59(11):1759-1765.PubMedCrossRefGoogle Scholar
  44. 44.
    Evans DGR, Ramsden R, Huson SM, et al. Type 2 neurofibromatosis: the need for supraregional care. J Laryngol Otol. 1993;107:401-406.PubMedCrossRefGoogle Scholar
  45. 45.
    Slattery WH, Brackmann DE, Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998;19:638-643.PubMedGoogle Scholar
  46. 46.
    Baser ME, Friedman JM, Aeschilman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet. 2002;71:715-723.PubMedCrossRefGoogle Scholar
  47. 47.
    Sobel RA, Wang Y. Vestibular (acoustic) schwannomas: histological features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol. 1993;52:106-113.PubMedCrossRefGoogle Scholar
  48. 48.
    Rowe JG, Radatz M, Walton L, Kemeny AA. Stereotactic radiosurgery for type 2 neurofibromatosis acoustic neuromas: patient selection and tumour size. Stereotact Funct Neurosurg. 2002;79:107-116.PubMedCrossRefGoogle Scholar
  49. 49.
    Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry. 2003;74(9):1288-1293.PubMedCrossRefGoogle Scholar
  50. 50.
    Baser ME, Evans DGR, Jackler RK, Sujansky E, Rubenstein A. Malignant peripheral nerve sheath tumours, radiotherapy, and neurofibromatosis 2. Br J Cancer. 2000;82:998.PubMedCrossRefGoogle Scholar
  51. 51.
    Evans DGR, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour-prone syndromes. J Med Genet. 2006;43(4):289-294.PubMedCrossRefGoogle Scholar
  52. 52.
    Evans DG, Kalamarides M, Hunter-Schaedle K, et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009;15:5032-5039.PubMedCrossRefGoogle Scholar
  53. 53.
    Hanemann CO. Magic but treatable? Tumours due to loss of merlin. Brain. 2008;131(pt 3):606-615.PubMedCrossRefGoogle Scholar
  54. 54.
    Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367.PubMedCrossRefGoogle Scholar
  55. 55.
    Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol. 2010;12(1):14-18.PubMedCrossRefGoogle Scholar
  56. 56.
    Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet. 1994;52:450-451.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • D. Gareth R. Evans
    • 1
  1. 1.Manchester Academic Health Science CentreSaint Mary’s HospitalManchesterUK

Personalised recommendations